EMPIRICUS micafungin versus placebo during nosocomial sepsis in Candida multi-colonized ICU patients with multiple organ failures: study protocol for a randomized controlled trial

Jean-François Timsit, Elie Azoulay, Muriel Cornet, Jean-Pierre Gangneux, Vincent Jullien, Aurélien Vésin, Edith Schir, Michel Wolff, Jean-François Timsit, Elie Azoulay, Muriel Cornet, Jean-Pierre Gangneux, Vincent Jullien, Aurélien Vésin, Edith Schir, Michel Wolff

Abstract

Background: The potential interest of antifungal treatment of non-immunocompromized patients with sepsis, extra-digestive Candida colonization and multiple organ failure is unknown. It represents three-quarters of antifungals prescribed in Intensive Care Units. It may allow early treatment of invasive fungal infection in the incubation phase but expose patients to unnecessary antifungal treatments with subsequent cost and fungal selection pressure. As early diagnostic tests for invasive candidiasis are still considered to be insufficient, the potential interest in this strategy needs to be demonstrated.

Methods: This prospective multicenter, double blind, randomized-controlled trial is conducted in 23 French Intensive Care Units. All adult patients, mechanically ventilated for more than four days with sepsis of unknown origin and with at least one extradigestive fungal colonization site and multiple organ failure are eligible for randomization. Patients with proven invasive candidiasis are not included. After a complete mycological screening, patients are allocated to receive micafungin 100 mg intravenously once a day or placebo for 14 days. We plan to enroll 260 patients. The main objective is to demonstrate that micafungin increases survival of patients without invasive candidiasis at day 28 as compared to placebo. Other outcomes include day 28 and 90 survival and organ failure evolution. Additionally, pharmacokinetics of micafungin in enrolled patients will be measured and evolution of fungal biomarkers and susceptibility profiles of infecting fungi will also be followed.

Discussion: This study will help to provide guidelines for treating non-immunocompromized patients with fungal colonization multiple organ failure and sepsis of unknown origin.

Trial registration: Clinicaltrials.gov number NCT01773876.

References

    1. Blumberg HM, Jarvis WR, Soucie JM, Edwards JE, Patterson JE, Pfaller MA, Rangel-Frausto MS, Rinaldi MG, Saiman L, Wiblin RT, Wenzel RP. Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study The National Epidemiology of Mycosis Survey. Clin Infect Dis. 2001;33:177–186. doi: 10.1086/321811.
    1. Rangel-Frausto MS, Wiblin T, Blumberg HM, Saiman L, Patterson J, Rinaldi M, Pfaller M, Edwards JE Jr, Jarvis W, Dawson J, Wenzel RP. National epidemiology of mycoses survey (NEMIS): variations in rates of bloodstream infections due to Candida species in seven surgical intensive care units and six neonatal intensive care units. Clin Infect Dis. 1999;29:253–258. doi: 10.1086/520194.
    1. Garrouste-Orgeas M, Timsit JF, Tafflet M, Misset B, Zahar JR, Soufir L, Lazard T, Jamali S, Mourvillier B, Cohen Y. et al.Excess risk of death from intensive care unit-acquired nosocomial bloodstream infections: a reappraisal. Clin Infect Dis. 2006;42:1118–1126. doi: 10.1086/500318.
    1. Pittet D, Li N, Woolson RF, Wenzel RP. Microbiological factors influencing the outcome of nosocomial bloodstream infections: a six-year validated, population-based model. Clin Infect Dis. 1997;24:1068–1078. doi: 10.1086/513640.
    1. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis. 2004;39:309–317. doi: 10.1086/421946.
    1. Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, Moreno R, Lipman J, Gomersall C, Sakr Y, Reinhart K. International study of the prevalence and outcomes of infection in intensive care units. Jama. 2009;302:2323–2329. doi: 10.1001/jama.2009.1754.
    1. Charles PE, Dalle F, Aube H, Doise JM, Quenot JP, Aho LS, Chavanet P, Blettery B. Candida spp. colonization significance in critically ill medical patients: a prospective study. Intensive Care Med. 2005;31:393–400. doi: 10.1007/s00134-005-2571-y.
    1. Pittet D, Monod M, Suter PM, Frenk E, Auckenthaler R. Candida colonization and subsequent infections in critically ill surgical patients. Ann Surg. 1994;220:751–758. doi: 10.1097/00000658-199412000-00008.
    1. Eggimann P, Garbino J, Pittet D. Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect Dis. 2003;3:685–702. doi: 10.1016/S1473-3099(03)00801-6.
    1. Leon C, Alvarez-Lerma F, Ruiz-Santana S, Leon MA, Nolla J, Jorda R, Saavedra P, Palomar M. Fungal colonization and/or infection in non-neutropenic critically ill patients: results of the EPCAN observational study. Eur J Clin Microbiol Infect Dis. 2009;28:233–242. doi: 10.1007/s10096-008-0618-z.
    1. Eggimann P, Bille J, Marchetti O. Diagnosis of invasive candidiasis in the ICU. Ann Intensive Care. 2011;1:37. doi: 10.1186/2110-5820-1-37.
    1. Leon C, Ruiz-Santana S, Saavedra P, Galvan B, Blanco A, Castro C, Balasini C, Utande-Vazquez A, de Molina FJG, Blasco-Navalproto MA. et al.Usefulness of the ‘Candida score’ for discriminating between Candida colonization and invasive candidiasis in non-neutropenic critically ill patients: a prospective multicenter study. Crit Care Med. 2009;37:1624–1633. doi: 10.1097/CCM.0b013e31819daa14.
    1. Ostrosky-Zeichner L. Issues in the design and interpretation of antifungal drug trials in the critically ill. Curr Opin Infect Dis. 2009;22:564–567. doi: 10.1097/QCO.0b013e328331fc5f.
    1. Garey KW, Rege M, Pai MP, Mingo DE, Suda KJ, Turpin RS, Bearden DT. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis. 2006;43:25–31. doi: 10.1086/504810.
    1. Grim SA, Berger K, Teng C, Gupta S, Layden JE, Janda WM, Clark NM. Timing of susceptibility-based antifungal drug administration in patients with Candida bloodstream infection: correlation with outcomes. J Antimicrob Chemother. 2012;67:707–714. doi: 10.1093/jac/dkr511.
    1. Labelle AJ, Micek ST, Roubinian N, Kollef MH. Treatment-related risk factors for hospital mortality in Candida bloodstream infections. Crit Care Med. 2008;36:2967–2972. doi: 10.1097/CCM.0b013e31818b3477.
    1. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother. 2005;49:3640–3645. doi: 10.1128/AAC.49.9.3640-3645.2005.
    1. Ostrosky-Zeichner L, Pappas PG. Invasive candidiasis in the intensive care unit. Crit Care Med. 2006;34:857–863. doi: 10.1097/01.CCM.0000201897.78123.44.
    1. Guery BP, Arendrup MC, Auzinger G, Azoulay E, Borges Sa M, Johnson EM, Muller E, Putensen C, Rotstein C, Sganga G. et al.Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients: Part I Epidemiology and diagnosis. Intensive Care Med. 2009;35:55–62. doi: 10.1007/s00134-008-1338-7.
    1. Marchetti O, Bille J, Fluckiger U, Eggimann P, Ruef C, Garbino J, Calandra T, Glauser MP, Tauber MG, Pittet D. Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991 to 2000. Clin Infect Dis. 2004;38:311–320. doi: 10.1086/380637.
    1. San Miguel LG, Cobo J, Otheo E, Sanchez-Sousa A, Abraira V, Moreno S. Secular trends of candidemia in a large tertiary-care hospital from 1988 to 2000: emergence of Candida parapsilosis. Infect Control Hosp Epidemiol. 2005;26:548–552. doi: 10.1086/502582.
    1. Cruciani M, de Lalla F, Mengoli C. Prophylaxis of Candida infections in adult trauma and surgical intensive care patients: a systematic review and meta-analysis. Intensive Care Med. 2005;31:1479–1487. doi: 10.1007/s00134-005-2794-y.
    1. Garbino J, Lew DP, Romand JA, Hugonnet S, Auckenthaler R, Pittet D. Prevention of severe Candida infections in nonneutropenic, high-risk, critically ill patients: a randomized, double-blind, placebo-controlled trial in patients treated by selective digestive decontamination. Intensive Care Med. 2002;28:1708–1717. doi: 10.1007/s00134-002-1540-y.
    1. Jacobs S, Price Evans DA, Tariq M, Al Omar NF. Fluconazole improves survival in septic shock: a randomized double-blind prospective study. Crit Care Med. 2003;31:1938–1946. doi: 10.1097/01.CCM.0000074724.71242.88.
    1. Pelz RK, Hendrix CW, Swoboda SM, Diener-West M, Merz WG, Hammond J, Lipsett PA. Double-blind placebo-controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients. Ann Surg. 2001;233:542–548. doi: 10.1097/00000658-200104000-00010.
    1. Playford EG, Webster AC, Sorrell TC, Craig JC. Antifungal agents for preventing fungal infections in non-neutropenic critically ill and surgical patients: systematic review and meta-analysis of randomized clinical trials. J Antimicrob Chemother. 2006;57:628–638. doi: 10.1093/jac/dki491.
    1. Shorr AF, Chung K, Jackson WL, Waterman PE, Kollef MH. Fluconazole prophylaxis in critically ill surgical patients: a meta-analysis. Crit Care Med. 2005;33:1928–1935. doi: 10.1097/01.CCM.0000178352.14703.49. Quiz 1936.
    1. Piarroux R, Grenouillet F, Balvay P, Tran V, Blasco G, Millon L, Boillot A. Assessment of preemptive treatment to prevent severe candidiasis in critically ill surgical patients. Crit Care Med. 2004;32:2443–2449. doi: 10.1097/01.CCM.0000147726.62304.7F.
    1. Schuster MG, Edwards JE Jr, Sobel JD, Darouiche RO, Karchmer AW, Hadley S, Slotman G, Panzer H, Biswas P, Rex JH. Empirical fluconazole versus placebo for intensive care unit patients: a randomized trial. Ann Intern Med. 2008;149:83–90. doi: 10.7326/0003-4819-149-2-200807150-00004.
    1. Montravers P, Dupont H, Gauzit R, Veber B, Auboyer C, Blin P, Hennequin C, Martin C. Candida as a risk factor for mortality in peritonitis. Crit Care Med. 2006;34:646–652. doi: 10.1097/01.CCM.0000201889.39443.D2.
    1. Pappas PG, Kauffman CA, Andes D, Benjamin DK Jr, Calandra TF, Edwards JE Jr, Filler SG, Fisher JF, Kullberg BJ, Ostrosky-Zeichner L. et al.Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;48:503–535. doi: 10.1086/596757.
    1. Azoulay E, Garrouste M, Goldgran-Toledano D, Adrie C, Max A, Vesin A, Francais A, Zahar JR, Cohen Y, Allaouchiche B. et al.Increased nonbeneficial care in patients spending their birthday in the ICU. Intensive Care Med. 2012;38:1169–1176. doi: 10.1007/s00134-012-2510-7.
    1. Laupland KB, Zahar JR, Adrie C, Minet C, Vesin A, Goldgran-Toledano D, Azoulay E, Garrouste-Orgeas M, Cohen Y, Schwebel C. et al.Severe hypothermia increases the risk for intensive care unit-acquired infection. Clin Infect Dis. 2012;54:1064–1070. doi: 10.1093/cid/cir1033.
    1. Machin D, Campbell M, Fayers P, Pinol A. Sample Size Tables for Clinical Studies. 2. Blackwell science: Malden, MA, USA; 1997.
    1. Azoulay E, Dupont H, Tabah A, Lortholary O, Stahl JP, Francais A, Martin C, Guidet B, Timsit JF. Systemic antifungal therapy in critically ill patients without invasive fungal infection*. Crit Care Med. 2012;40:813–822. doi: 10.1097/CCM.0b013e318236f297.
    1. Kett DH, Azoulay E, Echeverria PM, Vincent JL. Candida bloodstream infections in intensive care units: analysis of the extended prevalence of infection in intensive care unit study. Crit Care Med. 2011;39:665–670. doi: 10.1097/CCM.0b013e318206c1ca.
    1. Posteraro B, De Pascale G, Tumbarello M, Torelli R, Pennisi MA, Bello G, Maviglia R, Fadda G, Sanguinetti M, Antonelli M. Early diagnosis of candidemia in intensive care unit patients with sepsis: a prospective comparison of (1→3)-beta-D-glucan assay, Candida score, and colonization index. Critical Care (London, England) 2011;15:R249. doi: 10.1186/cc10507.
    1. Held J, Kohlberger I, Rappold E, Busse Grawitz A, Hacker G. Comparison of (1 → 3)-beta-D-glucan, mannan/anti-mannan antibodies, and Cand-Tec Candida antigen as serum biomarkers for candidemia. J Clin Microbiol. 2013;51:1158–1164. doi: 10.1128/JCM.02473-12.
    1. Sims CR, Jaijakul S, Mohr J, Rodriguez J, Finkelman M, Ostrosky-Zeichner L. Correlation of clinical outcomes with beta-glucan levels in patients with invasive candidiasis. J Clin Microbiol. 2012;50:2104–2106. doi: 10.1128/JCM.00773-12.
    1. Jaijakul S, Vazquez JA, Swanson RN, Ostrosky-Zeichner L. (1 → 3)-beta-D-glucan as a prognostic marker of treatment response in invasive candidiasis. Clin Infect Dis. 2012;55:521–526. doi: 10.1093/cid/cis456.
    1. Clancy CJ, Nguyen MH. Finding the ‘missing 50%’ of invasive candidiasis: how nonculture diagnostics will improve understanding of disease spectrum and transform patient care. Clin Infect Dis. 2013;56:1284–1292. doi: 10.1093/cid/cit006.
    1. Lortholary O, Desnos-Ollivier M, Sitbon K, Fontanet A, Bretagne S, Dromer F. Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2,441 patients. Antimicrob Agents Chemother. 2011;55:532–538. doi: 10.1128/AAC.01128-10.
    1. Pfaller MA, Castanheira M, Lockhart SR, Ahlquist AM, Messer SA, Jones RN. Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata. J Clin Microbiol. 2012;50:1199–1203. doi: 10.1128/JCM.06112-11.
    1. Dannaoui E, Desnos-Ollivier M, Garcia-Hermoso D, Grenouillet F, Cassaing S, Baixench MT, Bretagne S, Dromer F, Lortholary O. Candida spp. with acquired echinocandin resistance, France, 2004 to 2010. Emerg Infect Dis. 2012;18:86–90. doi: 10.3201/eid1801.110556.
    1. Fournier P, Schwebel C, Maubon D, Vesin A, Lebeau B, Foroni L, Hamidfar-Roy R, Cornet M, Timsit JF, Pelloux H. Antifungal use influences Candida species distribution and susceptibility in the intensive care unit. J Antimicrob Chemother. 2011;66:2880–2886. doi: 10.1093/jac/dkr394.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner